Announcement PDF 17th June 2015 ASX Release PharmAust Initiates Combination Therapy Evaluations in Canines Trial for treatment of Canine Cancers meets safety and activity endpoints PharmAust Limited (“PharmAust” or “the Company”) (ASX: PAA & PAAO) is pleased to announce that having reported that PPL-1 significantly suppressed a key cancer marker in two dogs evaluated, and has been safe and well tolerated by all the dogs treated with the drug so far (11 dogs in total), the Company and Veterinary Oncology Consultants have now decided to move to the next stage of clinical evaluations. The next stage of evaluations by Veterinary Oncology Consultants and PharmAust will make use of the “synergy” discovery (announced to the market 17th February 2014), which showed that PPL-1 has the potential to significantly enhance the anti-cancer activity of conventional chemotherapeutics without simultaneously enhancing the associated side-effect profile. In these evaluations dogs will be treated with a combination of “standard of care” chemotherapy and PPL-1. As of the date of this release, two dogs have received this combination therapy and are being monitored for the effects of the treatment on regression of their cancers. Principal investigator and dog cancer specialist, Dr Angela Frimberger, based at Veterinary Oncology Consultants Pty Ltd and the Animal Referral Hospital in Homebush, NSW said “We now know that not only is PPL-1 both safe and has biological activity in dogs, but also that it has the potential to improve the performance of chemotherapeutic drugs. This allows us to offer a new treatment option for dogs with resistant cancers. The dogs currently being treated have late stage cancers that are resistant to chemotherapy alone, and we will be measuring the effects of the combination on regression of their cancers; but we will also be evaluating first-line combination treatment”. The US companion pet market sales (est. 2011) are in the region of US$14 billion whilst cancer therapies are estimated at $550 million with a price point of around $1,500 per treatment. PharmAust’s Executive Chairman Dr Roger Aston said “As PPL-1 is already approved for veterinary use by PharmAust’s partner, a major global corporation in the Animal Health Industry, we believe that if successful in this trial, PPL-1 will be able to be approved quickly for the treatment of dog cancers following a further pivotal study”. *References: 2011-2012 National Pet Owners Survey Gabelli & Company, Inc. 2004. The US Veterinary health market. http://www.vet-dc.com/25.html American pet products manufacturers association, Inc. 2011-2012 National pet owner’s survey For further details please contact: Dr Roger Aston Executive Chairman Tel: 0402 762 204 rogeraston@pharmaust.com Mr Robert Bishop Executive Director Tel: 0417 445 180 robertbishop@pharmaust.com PharmAust Limited ABN 35 094 006 023. Suite 7, 29 The Avenue, Nedlands, Western Australia Tel: 08 9386 8767 Fax: 08 9389 1464 www.pharmaust.com